Search bioRxiv⌕ Search

Biology subjects

Corton, J. C.

Publications and source records attributed to Corton, J. C..

3 recordsLinked to original sources

Identification of co-expressed gene sets for major molecular initiating events in rodent liver carcinogenesis using wild type and knock out rats

Liver tumors are the most common carcinogenic outcome observed in two-year bioassays used for regulatory risk assessment of chemicals and pharmaceuticals. Because these traditional long-term studies are resource-intensive and not feasible for most chemicals, there is a critical need to develop alternative approaches that can identify potential rodent liver carcinogens in short-term studies (e.g., [≤] 1 month). Biomarkers associated with molecular initiating events (MIEs) of early rodent liver tumorigenesis may enable the prediction of two-year outcomes from such studies. Here, we identified transcriptional changes associated with six key initiators of rat liver tumorigenesis: five transcription factors (TFs) associated with non-genotoxic modes of action (AhR, PXR, CAR, PPAR, and ER), and tumor suppressor protein p53, which is activated by diverse cellular stressors including genotoxicity. Three known chemical activators for each TF were administered orally once daily for five days at doses associated with tumorigenic responses in previous rat cancer bioassays. RNA-seq identified differentially expressed genes (DEGs) that were consistently regulated by at least two activators in wild-type but not in corresponding TF knockout animals. Gene set enrichment analysis of ranked differential expression results demonstrated enrichment of pathways reflecting established TF biology. When comparing the consensus DEGs for each TF to a library of chemically induced, liver-specific gene expression profiles, we found that in most cases the chemicals with the most similar profiles to the consensus lists were known to activate the corresponding TF. Collectively, these findings identified candidate gene sets that may have utility for monitoring the induction of carcinogenesis-associated MIEs in short-term studies.

pharmacology and toxicology↗

Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice

BackgroundPer- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants with myriad adverse effects. While perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) are the most common contaminants, levels of replacement PFAS, such as perfluoro-2-methyl-3-oxahexanoic acid (GenX), are increasing. In rodents, PFOA, PFOS, and GenX have several adverse effects on the liver, including nonalcoholic fatty liver disease. ObjectiveWe aimed to determine human-relevant mechanisms of PFAS induced adverse hepatic effects using FRG liver-chimeric humanized mice with livers repopulated with functional human hepatocytes. MethodsMale humanized mice were treated with 0.067 mg/L of PFOA, 0.145 mg/L of PFOS, or 1 mg/L of GenX in drinking water for 28 days. Liver and serum were collected for pathology and clinical chemistry, respectively. RNA-sequencing coupled with pathway analysis was used to determine molecular mechanisms. ResultsPFOS caused a significant decrease in total serum cholesterol and LDL/VLDL, whereas GenX caused a significant elevation in LDL/VLDL with no change in total cholesterol and HDL. PFOA had no significant changes in serum LDL/VLDL and total cholesterol. All three PFAS induced significant hepatocyte proliferation. RNA-sequencing with alignment to the human genome showed a total of 240, 162, and 619 differentially expressed genes after PFOA, PFOS, and GenX exposure, respectively. Upstream regulator analysis revealed inhibition of NR1D1, a transcriptional repressor important in circadian rhythm, as the major common molecular change in all PFAS treatments. PFAS treated mice had significant nuclear localization of NR1D1. In silico modeling showed PFOA, PFOS, and GenX potentially interact with the DNA-binding domain of NR1D1. DiscussionThese data implicate PFAS in circadian rhythm disruption via inhibition of NR1D1. These studies show that FRG humanized mice are a useful tool for studying the adverse outcome pathways of environmental pollutants on human hepatocytes in situ.

pharmacology and toxicology↗

Transcriptome profiling reveals bisphenol A alternatives activate estrogen receptor alpha in human breast cancer cells

BackgroundPlasticizers with estrogenic activity, such as bisphenol A (BPA), have been reported to have potential adverse health effects in humans. Due to mounting evidence of these health effects and public pressure, BPA is being phased out by the plastics manufacturing industry and replaced by other bisphenol variants in \"BPA-free\" products.\n\nObjectivesWe have compared estrogenic activity of BPA to 6 bisphenol analogues (bisphenol S, BPS; bisphenol F, BPF; bisphenol AP, BPAP; bisphenol AF, BPAF; bisphenol Z, BPZ; bisphenol B, BPB) in three human breast cancer cell lines.\n\nMethodsEstrogenicity was assessed by cell growth in an estrogen receptor (ER)-mediated cell proliferation assay, and by the induction of estrogen response element (ERE)-mediated transcription in a luciferase assay. Gene expression profiles were determined in MCF-7 human breast cancer cells by microarray analysis and confirmed by Illumina-based RNA sequencing.\n\nResultsAll bisphenols showed estrogenic activity in promoting cell growth and inducing ERE-mediated transcription. BPAF was the most potent bisphenol, followed by BPB > BPZ ~ BPA > BPF ~ BPAP > BPS. The addition of ICI 182,780 antagonized the activation of ERs by bisphenols. Data mining of ToxCast high-throughput screening assays confirms our results but also shows divergence in the sensitivities of the assays. The comparison of transcriptome profile alterations resulting from BPA alternatives with an ER gene expression biomarker further indicates that all BPA alternatives act as ER agonists in MCF-7 cells. These results were confirmed by RNA sequencing.\n\nConclusionIn conclusion, BPA alternatives are not necessarily less estrogenic in a human breast cancer cell model. Three bisphenols (BPAF, BPB, and BPZ) were more estrogenic than BPA. The relevance of human exposure to BPA alternatives in hormone-dependent breast cancer risk should be investigated.

pharmacology and toxicology↗